TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05267821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: See information in arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: See information in arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: See information in arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: See information in arm/group descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See information in arm/group descriptions
Study: NCT05280548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat (GZ402671)
Description: Tablet; Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agalsidase alfa
Description: Concentrate for solution for infusion; IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agalsidase beta (GZ419828)
Description: Powder for concentrate for solution for infusion; IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Migalastat
Description: Hard capsules; Oral
Study: NCT06648759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulator
Description: The vagal nerve stimulator device is a nonsignificant risk device that provides electrical impulses to the vagus nerve, located in the neck and ear regions. The device (pulse generator) and a wire lead (insulated wire) with electrodes on the end of the wire will send the electrical signals along the vagus nerve to your brainstem to activate various neurochemical coordinates.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Vagal Nerve Stimulator
Description: The sham vagal nerve stimulator device is a nonsignificant risk device that mirrors that of the active stimulator but does not provide electrical impulses to the vagus nerve.
Study: NCT05975099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1975
Description: Dispersion delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1975
Description: Dispersion delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1975
Description: Dispersion delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1975
Description: Dispersion delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1982
Description: Dispersion delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1982
Description: Dispersion delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1982
Description: Dispersion delivered IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution delivered IM
Study: NCT06555822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an oral tablet once daily.
Study: NCT04915612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT05546411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Given by intravenous infusion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Combination of Chemo (Capecitabine) and Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Combination of Chemo (Capecitabine) and Radiation Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical removal of tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical removal of tumor
Study: NCT06036641

Intervention type: DEVICE
Intervention: NIRS monitoring
Description: All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.

Intervention type: DEVICE
Intervention: Laser Doppler flowmetry
Description: Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants

Intervention type: OTHER
Intervention: Inflammatory and Oxidative stress biomarkers
Description: Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
Study: NCT06464289

Intervention type: PROCEDURE
Intervention: Surgical stabilisation of rib fractures (SSRF)
Description: Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).

Intervention type: OTHER
Intervention: Non-operative management of rib fractures
Description: Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation.

Intervention type: OTHER
Intervention: Non-operative management of rib fractures
Description: Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation.
Study: NCT05323214

Intervention type: DRUG
Group type: OTHER
Intervention: Control Analgesic regimen
Description: testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl Analgesic regimen
Description: testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine Analgesic regimen
Description: testing the efficiency of Dexmedetomidine as an adjuvant drug to bupivacaine in epidural analgesia
Study: NCT06352268

Intervention type: PROCEDURE
Intervention: Pallidal, subthalamic or thalamic lesioning
Description: Radiofrequency, ultrasound guided or other lesioning procedures of the Globus pallidus interna, subthalamic nucleus or Vim nucleus of the thalamus for the management of Movement disorders
Study: NCT05909787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auto-questionnaire
Description: MCH (Montreal Children's Hospital) self questionnaire completed by the parents
Study: NCT05602467

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
Study: NCT05919264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOG-001
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6
Description: mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
Study: NCT05990127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin IV, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: carboplatin IV, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed IV, q3w (for Nonsquamous NSCLC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed IV, q3w (for Nonsquamous NSCLC)
Study: NCT05919264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6
Description: mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
Study: NCT05990127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV, q3w (for squamous NSCLC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel IV, q3w (for squamous NSCLC)
Study: NCT04922827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: single intravenous administration of 5 milligrams/kilogram
Study: NCT05919264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered per the prescribing information in combination with FOG-001
Study: NCT04922827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT05919264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered per the prescribing information in combination with FOG-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Description: Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Description: Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered per the prescribing information in combination with FOG-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered per the prescribing information in combination with FOG-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered per the prescribing information in combination with FOG-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered per the prescribing information in combination with FOG-001
Study: NCT04298684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METFORMIN
Description: After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control. In case of intolerance, the tolerated and effective dose will be taken back provided an effective glycemic control.~A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced.
Study: NCT05649410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with movement and conventional therapy
Description: Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sleeper stretch along with conventional therapy
Description: it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
Study: NCT06255977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CN-105
Description: Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
Study: NCT06419361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-Sa-DABI-4
Description: Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
Study: NCT06276491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb541
Description: Monoclonal bispecific antibody
Study: NCT05784714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOLA GEM
Description: This is a mobile application that has 6 psychoeducational sessions and related skills, local resources, and a way for participants to track their progress. Further information is in the arm descriptions.
Study: NCT05883631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation
Description: In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation
Description: In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow (EGF) mapping (no ablation)
Description: In addition to standard pulmonary vein isolation (PVI), subjects receive Electrographic Flow™ (EGF) mapping. PVI may be performed using any commercially available platform/catheter.~EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are marked as relevant; however, no EGF-guided ablations are performed during this index procedure. If subjects have AF recurrence after the 90-day blanking period, they may undergo a recurrence procedure and EGF-guided ablation.
Study: NCT06012006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: constant work-rate cycling exercise test
Description: Description: at the end of pulmonary rehabilitation, a constant work-rate second cycling exercise test will be performed with the same duration as the cycling exercise test at inclusion
Study: NCT06227741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept Mapping: as a Tool for Problem Based Learning
Description: Concept mapping is a visual representation and organizational tool that illustrates the relationships between concepts, ideas, and information. It involves creating a graphical depiction of knowledge, typically using nodes or boxes to represent concepts and connecting lines or arrows to signify the relationships between them. The central concept or main idea is often positioned in the center of the map, with subsidiary concepts branching out from it. These maps serve as a comprehensive overview of a subject, highlighting the hierarchical structure and interconnectedness of various elements.
Study: NCT06680271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote exercise
Description: The intervention group will consist of 25 subjects receiving a multicomponent physical exercise intervention (aerobic, strength, flexibility, and neuromotor) delivered by a physical therapist via the Microsoft Teams platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: The control group will consist of 25 subjects receiving traditional physical therapy at home from a physical therapist.